Trials / Completed
CompletedNCT04515043
EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754)
AN EXPLORATORY FOLLOW-UP STUDY OF LONG TERM ANTI-TELOMERASE IMMUNE RESPONSE AFTER INVAC-1 VACCINATION IN PATIENTS WITH LONG TERM SURVIVAL. Addendum to INVAC1-CT-101 PROTOCOL - EUDRACT NUMBER : 2013-004369-15
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Invectys · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will be an exploratory study of long term immunogenicity of INVAC-1 in patients who participated in the INVAC1-CT-101 phase I study (between 2014 and 2018).
Detailed description
The primary goal of the study is to analyze anti-telomerase specific memory responses in blood of long term survival patients and to correlate these immune responses to their subsequent treatment since the end of INVAC1-CT-101 phase I study. Six patients are expected to participate in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INVAC-1 given in the previous phase 1 NCT02301754. No new injection is required in this study. | blood sampling will be drawn once in order to analyse long term memory immune response to INVAC-1 vaccine |
Timeline
- Start date
- 2020-10-16
- Primary completion
- 2020-12-19
- Completion
- 2020-12-19
- First posted
- 2020-08-17
- Last updated
- 2021-06-01
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04515043. Inclusion in this directory is not an endorsement.